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Abstract
Background. Icodextrin is a glucose polymer derived by
hydrolysis of cornstarch. The different biocompatibility
profile of icodextrin-containing peritoneal dialysis (PD)
solutions may have a positive influence on peritoneal host
defence.Furthermore,casesofsterileperitonitispotentially
associated with icodextrin have been reported.
Methods. The primary objective of this multicentre, longi-
tudinal, observational, non-interventional, prospective co-
hort study, which included 722 PD patients, was to evaluate
the incidence of overall peritonitis in patients treated with
icodextrin-containingPDsolutions(ExtranealTM)useddur-
ing one long-dwell exchange/day compared with those
treated with non-icodextrin-containing PD solutions. The
secondary objective was to determine if culture-negative
peritonitis rates differed between patients treated with
icodextrin from two independent manufacturers. All peri-
tonitis episodes were assessed by a Steering Committee in
a blind manner.
Results. There was no significant difference between
icodextrin-treated and control patients in the adjusted over-
all, culture-positive or culture-negative peritonitis rates.
Whenstratifiedbytheicodextrinsupplier,therewasnosig-
nificant difference in the adjusted rate of culture-negative
peritonitis episodes between groups.
Conclusion. Subjects receiving icodextrin as part of their
PD regimen experienced neither a higher rate of culture-
negative peritonitis nor a lower rate of infectious peritonitis
compared with non-icodextrin users. There was no signif-
icant influence of the icodextrin raw material supplier on
peritonitis rates.
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Introduction
Icodextrin,aglucosepolymerderivedbyhydrolysisofcorn-
starch, is used as an alternative osmotic agent in peritoneal
dialysis (PD) solutions. Due to its high molecular weight
and slow absorption, icodextrin provides sustained peri-
toneal ultrafiltration for up to 16 h by the mechanism of
colloidal osmosis. It is, therefore, especially suitable for
the nighttime dwell in patients on continuous ambulatory
peritoneal dialysis (CAPD) and for the daytime dwell in
patients on automated peritoneal dialysis (APD). Several
studies report a significantly improved peritoneal fluid re-
moval, increased clearances of small solutes and middle
molecules, and a significant decrease of total body wa-
ter when icodextrin is prescribed for the long dwell in-
steadofconventional glucosesolutions[1–4].Accordingly,
icodextrin has been used as a salvage therapy in PD pa-
tients with refractory volume overload who were otherwise
abouttobetransferredtohaemodialysis[5,6].Furthermore,
some, but not all, studies suggested a positive influence
of icodextrin on hyperlipidaemia, on metabolic control in
diabetic PD patients and on the course of residual renal
function [3,6–11]. Because of these potential advantages,
icodextrin is a dialysis solution widely prescribed to PD
patients.
Among the most important side effects of icodextrin,
skin rash [12,13] and sterile peritonitis [14] have to be con-
sidered. On the other hand, it has been questioned if, due to
the lower content of glucose degradation products and the
iso-osmolality with plasma, icodextrin may have a positive
influence on peritoneal host defence [15–17]. Infectious
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peritonitis still constitutes one of the most important causes
of morbidity, technique failure and mortality in PD patients
[18–20]. The primary objective of this study was to investi-
gatepossibledifferencesinperitonitisrates(bothinfectious
andsterile)betweenPDpatientstreatedwithicodextrinand
patients treated exclusively with non-icodextrin solutions.
The secondary objective was to determine if there was a
relationshipbetweentheincidenceofculture-negativeperi-
tonitis and the icodextrin raw material supplier.
Subjects and methods
This multicentre, longitudinal, observational, non-inter-
ventionalprospectivecohortstudywasconductedat27cen-
tresinsevenEuropeancountries(Austria,Belgium,France,
Germany, Spain, Switzerland and UK). The maximum ob-
servation period was 2 years (inclusion of patients lasted
from 25 March 2003 to 22 December 2005). Both inci-
dent and prevalent PD patients (eligible age ≥18 and ≤
75years)treatedeitherwithCAPDorAPD(withorwithout
icodextrin) were included. Patients who had a past episode
of cloudy effluent possibly associated with icodextrin or
were only treated by one single dwell of icodextrin (which
was not part of an APD or CAPD regimen) were excluded
from this study. Patients currently on icodextrin after re-
challenge were eligible. Prevalent patients had been on
PD treatment for at least 3 months prior to study inclu-
sion. Incident patients were defined as those who were
on PD for <3 months at the time of inclusion. All pa-
tients provided written informed consent before inclusion.
The study was conducted in accordance with the gen-
eral ethical principles as expressed in the Declaration of
HelsinkiandinconformancewiththeInternationalConfer-
ence on Harmonisation Guidelines for Good Clinical Prac-
tice. Furthermore, written approval of the Local Research
EthicsCommitteewasobtainedbylocalinvestigatorswhen
required.
Study design
Since this was an observational, non-interventional study,
dialysis modality and solutions were chosen by the investi-
gator according to the individual patient’s needs. Based on
their prescription at enrolment, patients were categorized
as belonging to the icodextrin group or the control group.
The icodextrin group consisted of patients who were pre-
scribed icodextrin (Extraneal, Baxter Healthcare) once a
day for the single long dwell (nighttime dwell in CAPD
patients, daytime dwell in APD patients), with any other
solutions prescribed for the remaining exchanges. Patients
prescribed CAPD or APD without icodextrin constituted
to the control group. All PD solutions used for treatment
during the trial were obtained from routine commercial
sources. Icodextrin raw material was provided by two sup-
pliers (supplier A in Spain and Switzerland and supplier
B in Austria, Belgium, France, Germany and UK). Pre-
scription of concomitant medications was left to the physi-
cians involved in patient care and was based on clinical
requirements.
Study objectives
The primary objective of this study was to evaluate the
incidence of overall peritonitis (infectious and sterile) in
PD patients treated with icodextrin for one long dwell ex-
change per day as compared with patients treated exclu-
sively with non-icodextrin solutions. The secondary objec-
tive was to evaluate if the incidence of culture-negative
peritonitis between the icodextrin group and the control
group differed, based on the two independent icodextrin
suppliers.
Definition of peritonitis and peritonitis resolution
FortheblindeddatareviewbythestudySteeringCommittee
(see below), peritonitis was defined as a cloudy effluent
with >100 leukocytes/mm3. Each peritonitis episode was
further classified, depending on dialysate culture (culture
positive or culture negative).
Resolution of peritonitis was defined as the date of the
last dose of antibiotics (in cases where antibiotics were
used), or the date the symptoms disappeared (in cases
where no antibiotics were used), and/or the day the cell
count was <100/mm3 (if available). Relapsing peritonitis
was defined as an episode with the same organism or a
sterile episode that occurred within 4 weeks of completion
of antibiotic therapy of a prior peritonitis episode [21].
Since this was an observational study, diagnostic mea-
sures (including culture technique), choice of antibiotic
therapy and duration of treatment of peritonitis were left
to each investigator, dependent on each centre’s standard
practice.
Collection and analysis of data
In the case of peritonitis, the following data were collected
for each patient: start and end dates of peritonitis episodes,
clinical symptoms (e.g. fever, abdominal pain, nausea, di-
arrhoea), dialysate cell count, culture results, need for and
duration of hospitalization, need for and type of antibiotic
therapy, duration of therapy, time until peritonitis resolved,
outcome of peritonitis and need for switch to haemodialy-
sis. Besides peritonitis, no other adverse events had to be
reported by investigators in the case report forms, but the
investigators were asked to report serious adverse events
per standard pharmacovigilance routine.
All data recorded on the case report forms were dou-
ble entered into an electronic database using a clinical data
management system. Computerized data-cleaning checks
were used, together with manual reviews, to check for dis-
crepancies and to ensure the consistency of the data. An
electronic audit trail was used to track all data changes in
the database.
A Steering Committee, comprising four independent in-
vestigators from four different countries participating in
this study and three nephrologists of Baxter, reviewed all
collected data and performed individual causality assess-
ments for all peritonitis episodes. These members reviewed
each peritonitis episode while blinded to both the inter-
pretation of the other committee members and the solution
usedbythepatient.ThepresenceofBaxternephrologistsinIcodextrin and peritonitis rate 3713
the Steering Committee was considered to combine a local
andspecific(independentnephrologists)withageneraland
broad (Baxter nephrologists) perspective and overview of
the peritonitis cases. Baxter nephrologists certainly had the
most extensive experience with the icodextrin-associated
sterileperitonitisastheyhavethoroughlyreviewedallcases
reported through the pharmacovigilance system to Baxter
during these years as well as discussed a great deal of these
casespersonallywiththeinvolvednephrologiststhroughout
Europe. Each of the independent nephrologists had both a
long-term clinical experience with PD and their own clini-
cal experience with icodextrin-associated sterile peritonitis
episodes in their dialysis units. This combination of Bax-
terandindependentnephrologistsenabledustobringdepth
andsoundnesstothereviewprocess.However,tobenotde-
cisive when the independent nephrologists agreed on their
vote the three Baxter nephrologists had the right to only
one combined vote. In contrast to this ‘agreed upon’ one
vote by Baxter nephrologists, each independent nephrolo-
gist provided his/her own vote, resulting in a total of five
votes per peritonitis episode.
During the two study Steering Committee meetings, a
causal assessment was assigned to each peritonitis episode
(for association with dialysis solution) based on the WHO
causality definitions (the following definitions were used
for classification: certain, probably/likely, possible, un-
likely,conditional,notrelated,notassessable).Iftheculture
of dialysate was positive the diagnosis was of an infectious
peritonitis. Infectious peritonitis episodes were classified
as not related to icodextrin. If the culture was negative but
thepatientpresentedwithaclinicalpicturecompatiblewith
infectious peritonitis (fever, severe abdominal pain) and re-
sponded to antibiotic therapy, the episode was classified as
culture-negative peritonitis not related to icodextrin. In the
caseofdisagreementamongmembersoftheSteeringCom-
mittee, the treatment blind was broken and the clinical as-
sessment was discussed until a final decision was reached,
based on majority vote (with Baxter nephrologists’ vote
being counted as one vote only), and documented. The in-
dependent Steering Committee nephrologists were not paid
for their committee work, but were only reimbursed for
their travel expenses related to attending the two meetings.
Sample size calculation
Based on clinical reports and centre standards the average
pre-study peritonitis rate among non-icodextrin-treated PD
patients was estimated to be one episode every 28 patient
months. Assuming an annual dropout rate of 20% (40%
in 2 years), a power of 80% and a type I error rate of
0.025 (which was chosen to allow for sub-group analy-
ses), it was estimated that a sample of 250 patients in the
non-icodextrin arm and 500 patients in the icodextrin arm
would be needed to detect an overall peritonitis rate in-
crease of just over 50% in the icodextrin arm. To achieve
thesesamplesizes,a2:1samplingratiooficodextrintonon-
icodextrin users had to be selected. To minimize any bias
during inclusion of prevalent patients, investigators were
asked to select patients with the shortest interval between
the start of PD and study enrolment (minimum 3 months)
first, followed by patients with a longer PD history. When
assuming that icodextrin-treated patients were distributed
equally between both icodextrin suppliers, a sample size of
500 patients in the icodextrin arm (250 from each manu-
facturer) was also determined as necessary to detect, with
an estimated power of 70%, a 56% rate increase in peritoni-
tis rate. Therefore, a total of 750 patients were estimated
as an adequate sample size with a target goal of accruing
∼600 prevalent patients and ∼150 incident patients. No
sample size calculation was performed for analyses of the
rate of culture-negative peritonitis episodes, as this was a
secondary endpoint.
Statistics
Fortheprimaryobjective(overallperitonitisrate)anintent-
to-treat(ITT)analysiswasperformedcomparingperitonitis
rates between treatment groups (icodextrin and control) us-
ing Poisson regression techniques (gamma-Poisson regres-
sionmodelorstandardPoissonmodelwithoverdispersion)
according to the solutions used for treatment at the time
of enrolment, regardless of any subsequent changes that
mayhaveoccurredintreatmentsolutionutilization[22,23].
Peritonitis rates are expressed as the number of episodes
per patient year and results are summarized in terms of
both unadjusted (crude) and adjusted peritonitis rates along
with adjusted rate ratios (ARR) and corresponding 95%
confidence intervals. All comparisons between the icodex-
trin and control groups were adjusted for the baseline char-
acteristics of age, gender, treatment modality (CAPD or
APD) and diabetic status. The gamma-Poisson model (also
referred to as the negative binomial model) also adjusts
or accounts for subject-to-subject variability in individ-
ual peritonitis rates. Additionally, an as-treated analysis
was performed in which episodes of peritonitis and time
at risk were computed according to the actual treatment
solution and treatment modality a subject was receiving,
with treatment solution and treatment modality serving as
time-dependent covariates. Patients who dropped out due
to transfer to haemodialysis, death or kidney transplanta-
tion were censored at the time of dropout. Secondary ITT
and as-treated analyses were also performed, in which the
comparisons of culture-negative peritonitis stratified by the
manufacturer were adjusted for multiplicity using Bonfer-
ronicorrectedconfidenceintervalsandP-values.Allanaly-
sesutilizedrobuststandarderrorstoaccommodatepossible
intra-subject correlation in cases requiring the use of time-
dependent covariates.
Fordiscretevariables,thePearsonchi-squareandFisher’s
exact test were used to compare subjects’ baseline charac-
teristics (e.g. gender, age groupings, diabetic status) strat-
ified by their baseline solution (icodextrin versus non-
icodextrin). Student t-tests and Wilcoxon rank sum tests
were used to compare baseline differences between icodex-
trin and non-icodextrin treatment groups for continuous
measurements (e.g. baseline age). Lifetable techniques
wereusedtocomputeandcomparemedianresolutiontimes
associated with the duration of peritonitis episodes. To
accommodate those subjects with more than one episode
of peritonitis, a Cox proportional hazards model with ro-
bust standard errors was also used to analyse and com-
pare the distribution of resolution times for peritonitis.3714 A. Vychytil et al.
Table 1. Baseline characteristics of included patients
Icodextrin
group
Control
group
P-value
(n = 456) (n = 266)
Age (years) 54.4 ±
15.1
53.7 ±
14.3
0.397
Female/male (%) 34.6/65.4 48.9/51.1 <0.001
Time on peritoneal dialysis
(months)
23.0 ±
22.8
18.4 ±
22.4
<0.001
CAPD/APD (%) 39.5/60.5 65.0/35.0 <0.001
Diabetes (%) 30.5 18.4 <0.001
History of peritonitis (%) 34.6 24.1 0.003
History of exit site infection (%) 27.0 20.7 0.058
History of tunnel infection (%) 5.3 3.8 0.358
All analyses were done using the SAS statistical software
package (SAS Inc., Cary, NC, USA, version 9.1); in par-
ticular, the GENMOD procedure was used for the gamma-
Poisson regression analysis of peritonitis rates.
Results
Patient flow
A total of 722 patients (586 prevalent and 136 incident
patients) were enrolled in this study, corresponding to a to-
tal of 10860 patient-months. Numbers of APD and CAPD
patients were almost equal (369 and 353, respectively). Ac-
cording to the solutions used for treatment at the time of
enrolment, there were 456 patients in the icodextrin group
and 266 patients in the control group. Of the 456 patients
treated with icodextrin, 241 patients used icodextrin pro-
vided by supplier A, whereas 215 used icodextrin provided
by supplier B. During the observation period, some patients
changedfromicodextrintonon-icodextrinsolutionsorvice
versa. As a result, in the as-treated analysis these patients
were counted in both the icodextrin and control groups.
This is reflected in the number of patients reported for the
as-treated analysis which is higher than that reported for
the ITT analysis (icodextrin group, n = 543; control group,
n = 307).
Baseline characteristics (Table 1)
There was no significant difference in the mean age or age
distribution (data not shown) between treatment groups.
Compared with the control group, patients in the icodextrin
group had a significantly longer time on PD, and were
more likely to be male, diabetic or on APD. There were,
however, no significant differences in the type of diabetes
orthemeantimefromdiagnosisofdiabetestoenrolmentin
the study (data not shown). Significantly more patients in
theicodextringrouphadahistoryofperitonitisascompared
withcontrolsubjects,whereastherewasnodifferenceinthe
history of exit site and tunnel infections (Table 1). The time
since the last episode of peritonitis, exit site infection or
tunnel infection to the enrolment date was similar between
the groups (data not shown).
Table 2. Overall peritonitis rates (episodes/year; 95% CI) and adjusted
rate ratio (95% CI) of the icodextrin and the control group
Icodextrin
group
Control
group
Adjusted
rate ratio
P-value
Intent-to-treat (ITT)
analysis
Patient number (n) 456 266
Overall peritonitis episodes
(n)
229 136
Unadjusted rate
(episodes/year)
0.409 0.393
Adjusteda rate
(episodes/year)
0.407
(0.351;
0.472)
0.406
(0.324;
0.508)
1.003
(0.762;
1.321)
0.981
As-treated analysis
Patient number (n) 543 307
Overall peritonitis episodes
(n)
257 108
Unadjusted rate
(episodes/year)
0.415 0.379
Adjusteda rate
(episodes/year)
0.417
(0.363;
0.480)
0.386
(0.303;
0.492)
1.080
(0.819;
1.424)
0.595
aAdjusted for subject-to-subject variability, baseline characteristics (gen-
der, age and diabetic status) and either baseline treatment modality and
baselinesolution(ITTanalysis)ortime-dependenttreatmentmodalityand
time-dependent solution (as-treated analysis).
Comparison of overall peritonitis rates between
the icodextrin and the control group
In total, 365 peritonitis episodes were reported. Neither in
the ITT analysis nor in the as-treated analysis was there a
significant difference in the overall peritonitis rate between
patients in the icodextrin group and control patients when
adjusted for subject-to-subject variability, baseline charac-
teristics and treatment modality (Table 2). There were only
21 relapses, which were included in the analysis.
Accordingtotheprotocoltheeligibleagewas≤75years.
However, 19 patients older than 75 were included in the
study (received sponsor approval). Exclusion of these pa-
tients from the ITT or the as-treated analysis of adjusted
overall peritonitis rates had no influence on study results
(data not shown). Furthermore, inclusion or exclusion of
six patients with prior peritonitis episodes that were possi-
bly related to icodextrin yielded comparable results (data
not shown).
The median time to resolution of the peritonitis episode
was 14 days in both treatment groups. No statistically sig-
nificantdifferencesinthedurationoftheperitonitisepisode
were observed between icodextrin-treated and control pa-
tients or between CAPD patients and APD patients (data
not shown).
Comparison of peritonitis rates by culture results
Only as-treated analyses were performed for these calcula-
tions. Within the observation period, 303 of the 365 peri-
tonitis episodes were culture-positive (211 episodes in 543
patients in the icodextrin group and 92 episodes in 307
patients in the control group). Dialysate cultures were neg-
ative in 62 of the total of 365 episodes of peritonitis (17%).Icodextrin and peritonitis rate 3715
Table 3. Rates of culture-positive and culture-negative peritonitis (episodes/year; 95% CI) in PD patients of the icodextrin and the control group
(as-treated analysis)
Icodextrin group Control group Adjusted rate ratio P-value
(Patients: n = 543) (Patients: n = 307)
Culture-positive peritonitis
Peritonitis episodes (n) 211 92
Unadjusted rate (episodes/year) 0.340 0.323
Adjusteda rate (episodes/year) 0.331 (0.284; 0.386) 0.329 (0.254; 0.427) 1.006 (0.750; 1.349) 0.969
Culture-negative peritonitis
Peritonitis episodes (n)4 6 1 6
Unadjusted rate (episodes/year) 0.074 0.056
Adjusteda rate (episodes/year) 0.078 (0.057; 0.107) 0.052 (0.030; 0.091) 1.498 (0.779; 2.880) 0.233
aAdjusted for subject-to-subject variability, baseline characteristics (gender, age and diabetic status), time-dependent treatment modality and time-
dependent solution.
The rate of culture-negative peritonitis was 18% in the
icodextrin group (46 of 257 episodes) and 15% in the con-
trol group (16 of 108 episodes). Forty (7.4%) of the 543
patients of the icodextrin group and 16 (5.2%) of the 307
control patients had at least one episode of culture-negative
peritonitis (P = 0.226).
No significant differences between treatment groups
were observed in the adjusted rates of culture-positive or
culture-negative peritonitis (Table 3).
Comparison of peritonitis rates by icodextrin supplier
Whentheadjustedoverall peritonitisratesbetween patients
in the icodextrin group and those in the control group were
analysed per icodextrin raw material supplier, no statisti-
cally significant differences were observed in either the
ITT or the as-treated analysis (Figure 1).
When stratified by the supplier, the adjusted rates of
culture-negative peritonitis episodes tended to be higher in
the icodextrin group compared with the control group for
supplier A (not significant), whereas there was no differ-
ence between treatment groups for supplier B (Figure 2). It
is interesting to note that five of the culture-negative peri-
tonitisepisodesintheicodextringroupoccurredinonlytwo
patients of one investigational centre that was supplied by
providerA.Consideringthatthisstudyisstrictlyaprospec-
tiveobservationalandunblindedstudynotpoweredtoanal-
yse the incidence of culture-negative peritonitis episodes, it
is possible that any number of unmeasured, centre-specific
factors(e.g.relatedtolaboratorytechniquesorunmeasured
patient characteristics) may account for some or all of these
differences.
Association of peritonitis episodes with icodextrin
After a blind review by each individual member of the
Steering Committee there was unanimous concordance be-
tween independent nephrologists and Baxter nephrologists
in 293 of the 365 cases of peritonitis (80.3%) reported and
reviewed in this study. In 47 of the remaining 72 cases the
independent nephrologists either had together a unanimous
vote (n = 28) or the majority of the independent nephrolo-
gists had a vote which prevailed against the isolated Baxter
nephrologists’ vote and one of the independent nephrolo-
gists’ different vote (n = 19). There were six cases with a
tieand19caseswherealltheblindedreviewsledtodifferent
interpretations among all voters. In these 25 cases (6.8%),
the final decision on the causal assessment was taken af-
ter discussion among all members in a meeting, where the
Baxter vote was still considered as one only, while each
independent nephrologist again had his/her own vote. All
the information of the Steering Committee meetings and
votes has been documented.
Of the 365 peritonitis episodes reported, 364 episodes
were classified by the Steering Committee. Of these 364
episodes, 355 were classified as not related to the solution
prescribed (icodextrin or non-icodextrin). Three culture-
negative episodes were classified as unlikely related to
icodextrin (hospitalization was required in one of these
three cases). Six episodes (all culture negative), which oc-
curred in four patients, were classified as possibly related
to icodextrin treatment. None of these episodes required
hospitalization. Five of the six possibly related peritonitis
episodes and two of the three unlikely related sterile peri-
tonitis episodes occurred at one single investigational site,
with one patient experiencing three of these six peritoni-
tis episodes (data not shown). One of the 365 peritonitis
episodes was not classified by the Steering Committee be-
cause of a lack of sufficient available information.
Withdrawals and deaths
Excluding patients who were withdrawn when the study
ended (December 2005), a total of 421 subjects (282 in
the icodextrin group, 139 in the control group) withdrew
early from the study. This dropout rate of 49.5 per 100
patient-years in the icodextrin group and 39.4 withdrawals
per 100 patient-years in the control group was higher than
the 20% annual withdrawal rate expected in the sample
size calculation. When considering the actual peritonitis
rate and total number of treatment months reported in the
presenttrial,thishigherdropoutratehadlittleimpactonthe
overallpowerofthestudytodetectadifferenceinperitonitis
rates of just over 50% between groups (observed power
after considering the higher dropout rate: 76% versus target
power when assuming a 20% annual dropout rate: 80%).
Peritonitis was the reason for study discharge in 37/456
patients in the icodextrin group (8.1%) and in 17/2663716 A. Vychytil et al.
Fig. 1. Analysis of overall peritonitis rates in episodes (ep)/year: icodextrin versus control group, by supplier
Fig. 2. Analysis of culture-negative peritonitis rates in episodes (ep)/year: icodextrin versus control group, by supplier
patients in the control group (6.4%). A total of 97 of the
722 enrolled subjects died during the observation period:
67/456 patients (14.7%) in the icodextrin group and 30/266
patients (11.3%) in the control group. None of these deaths
were considered to be related to the use of the prescribed
dialysis solutions. Since this was an observational study, no
further data on reason of deaths were requested.
There was no significant difference between the icodex-
trin group and the control group in the percent of pa-
tients withdrawn from the study because of peritonitis
(P = 0.396), death (P = 0.194) or any other reason, in-
cluding kidney transplantation (23.5% versus 23.7%, P =
0.947) and transfer to haemodialysis (10.3% versus 6.8%,
P = 0.109).
Discussion
The use of icodextrin-containing dialysis solutions opti-
mizes peritoneal ultrafiltration, allows better fluid control
as compared with standard solutions [3], improves qual-
ity of life [24] and prolongs technique survival of PD pa-
tients [5,6]. An icodextrin-containing dialysis solution has
an acidic pH. However, in contrast to glucose-based stan-
dardsolutionsbothitsiso-osmolalitytoserumandthelower
content of glucose degradation products may improve the
biocompatibility profile of icodextrin. Accordingly, a sub-
analysis of data from the European APD Outcome Study
showed that peritoneal function was better preserved in
anuric APD patients using icodextrin during the daytime
dwell as compared with those treated with a glucose solu-
tion [25]. Furthermore, it could be hypothesized that the
greater proliferation of mesothelial cells [26] and improve-
ment of phagocytic function [15–17] reported by some
authors after exposure to icodextrin as compared with stan-
dard solutions may have a positive impact on decreasing
infectious peritonitis rates. However, a previous random-
ized study conducted in 1995 did not demonstrate a statis-
tically significant difference in the risk of peritonitis be-
tween CAPD patients treated with icodextrin and those
using glucose-based standard solutions [27]. These data
cannot be transferred to the present PD treatment reg-
imens because the PD technique has improved and the
number of APD patients has increased since that time.
These factors may account for the fact that the peritoni-
tis rate of both icodextrin- and non-icodextrin-treated pa-
tients in this observational trial was markedly lower than
that in the randomized study published by Gokal et al.
more than 10 years ago [27]. More importantly, the peri-
tonitis rates found in the present study in both treatment
groups were lower than the maximum acceptable target
of 1 episode/18 treatment months and 1 episode/24 treat-
ment months recommended by recent guidelines [21,28].
We found no difference in overall or culture-positive peri-
tonitis rates between patients treated with icodextrin and
those using exclusively non-icodextrin solutions, which is
in agreement with the above-mentioned earlier results, as
well as some more recent studies [2,17]. Additionally, in
the present trial, the duration of peritonitis was similar in
icodextrin-treated and control patients. However, because
of differences in local treatment practices and the variabil-
ity in definition of peritonitis resolution used by different
investigators, these latter results should be interpreted with
caution.
Besides infectious peritonitis, the question if icodex-
trin influences the incidence of culture-negativeIcodextrin and peritonitis rate 3717
peritonitis remains. A higher incidence of culture-negative
peritonitis may reflect inappropriate culture techniques
used formicrobiological analysis ofdialysate samples [21].
Episodes of sterile peritonitis have also been reported that
were caused by endotoxin contamination of the dialysis
solution,intraperitonealchemicalagents(includingglucose
degradation products and several drugs), allergic mech-
anisms (including eosinophilic peritonitis) or, rarely, by
peritoneal metastases, pancreatitis and abdominal lym-
phomas [29–34]. Between November 2001 and July 2002,
a markedly increased incidence of sterile peritonitis as-
sociated with icodextrin treatment was reported [35–41].
These cases were caused by a peptidoglycan (released from
Alicyclobacillus acidocaldarius, a thermophilic acidophilic
Gram-positive organism contaminating the cornstarch used
for icodextrin production) [41]. Peptidoglycans induce pro-
inflammatory cytokine production of mononuclear cells,
though to a much lower extent than endotoxins [42]. After
implementation of routine serial monitoring of icodextrin
solutions for peptidoglycan during the manufacturing pro-
cess, the frequency of icodextrin-associated peritonitis de-
creased dramatically within a few months [41]. Neverthe-
less, a few recent cases have been reported [43]. Besides
common causes of culture-negative peritonitis (e.g. peri-
tonitiswithfalse-negativecultureoratypicalinfection)sev-
eral other reasons for these newer cases have been consid-
ered, including sensitization of patients to peptidoglycan or
icodextrin, or individual reaction of some patients to a level
of peptidoglycan below the detectable threshold [44,45].
However, it must be taken into account that sterile peri-
tonitis has always existed with glucose-based PD solutions,
even long before the introduction of icodextrin [46,47].
An increased incidence of culture-negative peritonitis may
result in unnecessary use of antibiotics or even catheter
removal. According to international guidelines, the rate of
culture-negative peritonitis should be <20% [21]. The in-
cidence of 17% for culture-negative peritonitis found in the
present trial meets this recommendation. Furthermore, in
this large population of PD patients from seven European
countries, the rate of culture-negative peritonitis did not
differ between icodextrin-treated and control patients, who
were mainly prescribed glucose-based PD solutions.
The incidence rate of peritonitis in icodextrin-treated pa-
tients between the two suppliers was not analysed because
each icodextrin supplier provided an entire country, mak-
ing it impossible to provide a rationale to stratify by coun-
try. Therefore, a difference between the two providers may
primarily reflect country-specific differences in peritonitis
rate, diagnosis and treatment of peritonitis, patient selec-
tion and/or laboratory techniques. However, when strati-
fied by the icodextrin supplier, no statistically significant
differences were observed in adjusted overall and culture-
negative peritonitis rates between patients in the icodextrin
group compared with patients in the control group. Based
on these results it appears that a significant influence of the
supplier on peritonitis rates in icodextrin-treated patients is
unlikely.
This study has certain limitations such as a non-
randomized study design and a heterogeneous patient pop-
ulation. However, randomization of patients into a con-
trol group without icodextrin was not acceptable to several
centres because of the fear of overhydration, especially in
patients with high peritoneal transport rates. Therefore, a
randomized design would have significantly reduced the
number of patients available for enrolment. Furthermore,
a randomized controlled trial is inappropriate for accurate
measurement of the frequency of rare events [48].
There were more diabetic patients and patients with
longer duration of dialysis before enrolment in the icodex-
trin group, and other than diabetic status, no data on co-
morbiditywererequestedinthisobservationalstudy.There-
fore, despite adjustment for age, gender, PD modality and
diabetic status a selection bias cannot be excluded. For ex-
ample, patients with higher co-morbidity, including those
with diabetes, have faster peritoneal solute transport rates
[49] and are therefore more likely to receive icodextrin.
Regardless of dialysis prescription, these patients may also
have a higher risk of infectious peritonitis [50,51]. Con-
sequently, a higher peritonitis rate (if anything) could be
expected in icodextrin-treated patients compared with con-
trol patients, which, however, was not the case in this study.
As mentioned above sterile peritonitis may be of dif-
ferent aetiologies, but a significant part of these episodes
are infectious cases that remain culture-negative. If a pa-
tient with culture-negative peritonitis responds to antibiotic
therapy, it is highly likely that this is an infectious episode.
However, even in this case an association with icodextrin
(or any other dialysis solution) cannot be completely ruled
out. A spectrum of diagnostic measures would have to be
available to evaluate the pathogenesis of culture-negative
peritonitis and its possible association with icodextrin. Per-
forming all these tests in each episode of sterile peritonitis,
however, goes beyond the scope of an observational trial
including almost 30 centres. Instead of that, the Steering
Committee, after a blinded review, classified each episode
of peritonitis (based on clinical data and routine laboratory
resultsprovidedbyeachinvestigator).Basedonthesevotes,
an association with icodextrin could not be completely ex-
cluded in <10 out of 365 peritonitis episodes. It has to
be considered that sterile peritonitis usually is a sporadic
event. Therefore, the fact that we did not find a significant
difference in peritonitis rates between icodextrin and non-
icodextrin patients or between the two providers does not
preclude that in future other cases or even clusters of sterile
peritonitis (associated with icodextrin or any other dialysis
solution) could reappear.
In summary, this study further supports that icodextrin
provided by both raw material suppliers is safe to use as a
single daily exchange that is part of a PD regimen, as being
done daily by >10 000 patients in Europe today. There was
neither a higher rate of culture-negative peritonitis nor a
lower rate of infectious peritonitis experienced in subjects
receiving icodextrin as part of CAPD or APD regimens
compared with non-icodextrin users.
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